Robert Sidbury1, Kate Khorsand2. 1. Department of Pediatrics, Division of Dermatology, Seattle Childrens Hospital, University of Washington School of Medicine, OC 9.835, Seattle Childrens Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. Robert.sidbury@seattlechildrens.org. 2. Department of Pediatrics, Division of Dermatology, Seattle Childrens Hospital, University of Washington School of Medicine, OC 9.835, Seattle Childrens Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA.
Abstract
PURPOSE OF REVIEW: Tremendous advances have been made in the field of atopic dermatitis in the past 5 years. We will explore developments in burden of disease, co-morbidities, pathogenesis, prevention, and management. RECENT FINDINGS: The tremendous burden moderate to severe atopic dermatitis (AD) places on families from a medical, psychosocial, and financial perspective has been characterized. Epidemiologic studies have identified intriguing new associations beyond the well-characterized "atopic march" of food allergies, asthma, and hay fever. Studies of primary prevention have gained traction including the remarkable impacts of early emollient therapy. Basic advances have simultaneously elucidated the nature of atopic inflammation, setting the stage for an explosion of new potential therapeutic targets. After a fallow period of nearly 15 years without a substantial therapeutic advance, this year has already seen two new FDA-approved treatments for AD. AD has a tremendous impact on quality of life with an underappreciated burden of disease; there are important newly described co-morbidities including ADHD and anemia; new insights into etio-pathogenesis have paved the way for novel topical therapies like crisaborole, and new systemic interventions like dupilumab.
PURPOSE OF REVIEW: Tremendous advances have been made in the field of atopic dermatitis in the past 5 years. We will explore developments in burden of disease, co-morbidities, pathogenesis, prevention, and management. RECENT FINDINGS: The tremendous burden moderate to severe atopic dermatitis (AD) places on families from a medical, psychosocial, and financial perspective has been characterized. Epidemiologic studies have identified intriguing new associations beyond the well-characterized "atopic march" of food allergies, asthma, and hay fever. Studies of primary prevention have gained traction including the remarkable impacts of early emollient therapy. Basic advances have simultaneously elucidated the nature of atopic inflammation, setting the stage for an explosion of new potential therapeutic targets. After a fallow period of nearly 15 years without a substantial therapeutic advance, this year has already seen two new FDA-approved treatments for AD. AD has a tremendous impact on quality of life with an underappreciated burden of disease; there are important newly described co-morbidities including ADHD and anemia; new insights into etio-pathogenesis have paved the way for novel topical therapies like crisaborole, and new systemic interventions like dupilumab.
Entities:
Keywords:
Anemia; Atopic dermatitis; Attention deficit hyperactivity disorder; Crisaborole; Dupilumab; Emollient; Filaggrin; Quality of life
Authors: Amy S Paller; Wynnis L Tom; Mark G Lebwohl; Robin L Blumenthal; Mark Boguniewicz; Robert S Call; Lawrence F Eichenfield; Douglass W Forsha; William C Rees; Eric L Simpson; Mary C Spellman; Linda F Stein Gold; Andrea L Zaenglein; Matilda H Hughes; Lee T Zane; Adelaide A Hebert Journal: J Am Acad Dermatol Date: 2016-07-11 Impact factor: 11.527
Authors: F Turati; P Bertuccio; C Galeone; C Pelucchi; L Naldi; J-F Bach; C La Vecchia; L Chatenoud Journal: Allergy Date: 2016-03-04 Impact factor: 13.146
Authors: Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: Michelle G Filanovsky; Suwimon Pootongkam; Joan E Tamburro; Mary C Smith; Stephen J Ganocy; Susan T Nedorost Journal: J Pediatr Date: 2015-11-23 Impact factor: 4.406
Authors: Yujiao Meng; Zhengrong Liu; Chunyan Zhai; Tingting Di; Lu Zhang; Lei Zhang; Xinran Xie; Yan Lin; Ning Wang; Jingxia Zhao; Yan Wang; Ping Li Journal: Mol Med Rep Date: 2019-02-25 Impact factor: 2.952